TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33567005

Group type: EXPERIMENTAL
Intervention: GII: color retinography + visual field
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GIII: color retinography + optical coherence tomography
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GIV: color retinography + visual field + optical coherence tomography
Number of subjects: 80

Group type: COMPARATOR
Intervention: GI: color retinography
Number of subjects: 80

Group type: COMPARATOR
Intervention: GI
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GII
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GIII
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GIV
Number of subjects: 80
Study: 33274199

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tablet candy
Number of subjects: 46
Study: 35051941

Group type: EXPERIMENTAL
Intervention: rTMS to facilitate contralesional dorsal premotor cortex (cPMd) in conjunction with task-oriented upper limb rehabilitation
Number of subjects: 24

Group type: COMPARATOR
Intervention: rTMS to facilitate ipsilesional primary motor cortex (iM1) in conjunction with task-oriented upper limb rehabilitation
Number of subjects: 24
Study: 34351721

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose anticoagulation with heparin
Number of subjects: 2219

Group type: COMPARATOR
Intervention: Usual-care pharmacologic thromboprophylaxis
Number of subjects: 2219
Study: 33964053

Group type: EXPERIMENTAL
Intervention: Powered Tooth brushing (PT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Manual Tooth brushing (MT)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both PT and MT
Number of subjects: 46
Study: 33826633

Group type: EXPERIMENTAL
Intervention: Pavlovian cue-conditioning paradigm with glucose and water delivery
Number of subjects: 5
Study: 34121511

Group type: EXPERIMENTAL
Intervention: Boxing
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sensory Exercise
Number of subjects: 40
Study: 32062614

Group type: EXPERIMENTAL
Intervention: Higher left handgrip strength
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher right handgrip strength
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetically predicted CAD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetically instrumented body lean mass
Number of subjects: 0
Study: 35689805

Group type: EXPERIMENTAL
Intervention: tDCS plus FDS
Number of subjects: 32

Group type: COMPARATOR
Intervention: sham tDCS plus FDS
Number of subjects: 32
Study: 33926267

Group type: EXPERIMENTAL
Intervention: Logistic regression probability model with urn or permuted block randomization method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional beta-binomial probability model
Number of subjects: 0
Study: 32966290

Group type: EXPERIMENTAL
Intervention: Praziquantel plus Dihydroartemisinin-piperaquine combination
Number of subjects: 639

Group type: COMPARATOR
Intervention: Praziquantel alone
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 639
Study: 34615419

Group type: EXPERIMENTAL
Intervention: Olive oil dairy drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-lipid dairy drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-formed oleic acid micelle dairy drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fish oil dairy drink
Number of subjects: 0
Study: 32657958

Group type: EXPERIMENTAL
Intervention: Spanish language TAPS Tool (self-administered)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Spanish language TAPS Tool (interviewer-administered)
Number of subjects: 100
Study: 33332053

Group type: EXPERIMENTAL
Intervention: SEP-363856
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35123454

Group type: EXPERIMENTAL
Intervention: Transition program
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Peer support component
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Joint transfer meeting
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Engagement of adolescents and healthcare professionals
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Contextual factors
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Standard operating procedures
Number of subjects: 8
Study: 33105946

Group type: EXPERIMENTAL
Intervention: PiCCO monitoring rehydration group
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional rehydration group
Number of subjects: 52
Study: 35612354

Group type: EXPERIMENTAL
Intervention: Developing Inclusive Youth program (classroom-based, individually administered video tool with teacher-led discussions)
Number of subjects: 983

Group type: EXPERIMENTAL
Intervention: Developing Inclusive Youth program
Number of subjects: 983

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 983
Study: 33622326

Group type: EXPERIMENTAL
Intervention: VB‐HoLEP
Number of subjects: 200

Group type: COMPARATOR
Intervention: HoLEP
Number of subjects: 200
Study: 35139373

Group type: EXPERIMENTAL
Intervention: Maternal influenza vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 34848479

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 51
Study: 35772819

Group type: EXPERIMENTAL
Intervention: Knee Joint Distraction (KJD)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Knee Replacement (KR)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: KJD
Number of subjects: 344

Group type: COMPARATOR
Intervention: KR
Number of subjects: 344
Study: 33546968

Group type: EXPERIMENTAL
Intervention: Intraoperative fluid (IOF) administration at a rate of 11.90 mL/kg/h (higher IOF rate)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Intraoperative fluid (IOF) administration at a higher rate
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Tri‐incisional esophagectomy
Number of subjects: 1040
Study: 32847912

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) with a self-selected 10-hour eating window from 06:00 to 20:00
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Habitual living (control group)
Number of subjects: 100
Study: 35908555

Group type: EXPERIMENTAL
Intervention: Endoscopic sleeve gastroplasty (ESG) with lifestyle modifications
Number of subjects: 209

Group type: COMPARATOR
Intervention: Lifestyle modifications alone (control group)
Number of subjects: 209
Study: 33511727

Group type: EXPERIMENTAL
Intervention: Opalescence Boost (OB) 40%
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Diode laser‐assisted LaserWhite20 (LW20) 45%
Number of subjects: 180

Group type: COMPARATOR
Intervention: Unbleached control group
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Single Bond 2 (SB2) after 7 days
Number of subjects: 180
Study: 35473649

Group type: EXPERIMENTAL
Intervention: Do More, Feel Better (DMFB)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Behavioral Activation delivered by social workers (MSW BA)
Number of subjects: 56
Study: 32750626

Group type: EXPERIMENTAL
Intervention: Most intensive intervention group
Number of subjects: 595

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 595
Study: 33340263

Group type: EXPERIMENTAL
Intervention: Perampanel (2-12 mg/day)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Perampanel (8 mg/day)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 277
Study: 32314053

Group type: EXPERIMENTAL
Intervention: 14-week triathlon exercise training program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Untrained control group (n=16)
Number of subjects: 46
Study: 35133286

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral intervention with asynchronous therapist support
Number of subjects: 87

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 87
Study: 32234295

Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with Azacytidine (AZA) at 32 mg/m2 for 5 days every 28 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Preemptive treatment with Azacytidine (AZA) at 75 mg/m2 for 5 or 7 days per cycle
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions (DLIs)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GvHD) management
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Treatment suspension
Number of subjects: 32
Study: 35945827

Group type: EXPERIMENTAL
Intervention: Prediction model for diagnosing CRC using hemoglobin-to-platelet ratio, fibrinogen-albumin ratio (FAR), albumin-globulin ratio (A/G), platelet-lymphocyte ratio, carcinoembryonic antigen (CEA), and thrombin time (TT).
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Prediction model for diagnosing CRC stage using prothrombin time (PT), TT, CEA, A/G, FAR, and hemoglobin-to-platelet ratio (HPR).
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Prediction model for diagnosing CRC grade using PT, TT, A/G, plateletcrit, FAR, and HPR.
Number of subjects: 856
Study: 33637074

Group type: EXPERIMENTAL
Intervention: Parenteral ibuprofen
Number of subjects: 7000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000
Study: 32632546

Group type: EXPERIMENTAL
Intervention: Coronary CTA
Number of subjects: 180

Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 180
Study: 33608400

Group type: EXPERIMENTAL
Intervention: Inhaled sedation strategy
Number of subjects: 250

Group type: COMPARATOR
Intervention: Intravenous sedation strategy
Number of subjects: 250
Study: 32149826

Group type: EXPERIMENTAL
Intervention: Flexible duty-hour policy
Number of subjects: 3750
Study: 34294144

Group type: EXPERIMENTAL
Intervention: Baidu Jieduan granules (twice a day for 14 days)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 300
Study: 33901041

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation combined with neuromuscular electrical stimulation
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (conventional rehabilitation only)
Number of subjects: 26
Study: 32464822

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: HeartMate II (HMII)
Number of subjects: 1020
Study: 34518313

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg orally twice daily and capivasertib orally twice daily on a 4-day on 3-day off schedule (DL1: 400 mg, DL-1: 320 mg)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Olaparib 300 mg orally twice daily and capivasertib orally twice daily on a 4-day on 3-day off schedule
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Olaparib and capivasertib
Number of subjects: 38
Study: 32589237

Group type: EXPERIMENTAL
Intervention: Multi-orifice catheter (MOC)
Number of subjects: 58

Group type: COMPARATOR
Intervention: End-hole catheter (EHC)
Number of subjects: 58
Study: 34736073

Group type: EXPERIMENTAL
Intervention: 6-month multicomponent intervention
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study: 32819292

Group type: EXPERIMENTAL
Intervention: Extracorporeal blood purification (hemoadsorption) via resin-directed hemoperfusion using continuous renal replacement therapy (CVVH) for three sessions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Extracorporeal blood purification (hemoadsorption)
Number of subjects: 10
Study: 34343394

Group type: COMPARATOR
Intervention: Active stimulation for brachial plexus leads
Number of subjects: 61

Group type: COMPARATOR
Intervention: Active stimulation for sciatic nerve leads
Number of subjects: 61
Study: 33135552

Group type: EXPERIMENTAL
Intervention: Structured family meeting
Number of subjects: 297

Group type: COMPARATOR
Intervention: Control group (no family meeting)
Number of subjects: 297
Study: 32381160

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg or placebo administered subcutaneously every 2 weeks, titrated to 150 mg if LDL-C remained ≥50 mg/dl.
Number of subjects: 18924
Study: 35905318

Group type: EXPERIMENTAL
Intervention: 12-session group counseling course
Number of subjects: 1680

Group type: COMPARATOR
Intervention: Wait-listed (control group)
Number of subjects: 1680
Study: 33881579

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Inhalation Anesthesia (INHA) with desflurane (DES)
Number of subjects: 132
Study: 34842984

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 362

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: CST fluctuation quartiles (4th vs 1st)
Number of subjects: 362
Study: 33417284

Group type: EXPERIMENTAL
Intervention: Topical cetirizine 1% applied daily (1 mL) for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo solution applied daily (1 mL) for 6 months
Number of subjects: 60
Study: 32348537

Group type: EXPERIMENTAL
Intervention: Ranibizumab treatment
Number of subjects: 235
Study: 36210397

Group type: EXPERIMENTAL
Intervention: Achieve catheter-guided cryoballoon ablation with additional EnSite voltage maps
Number of subjects: 100

Group type: COMPARATOR
Intervention: Achieve catheter-guided cryoballoon ablation (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Achieve Plus group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 32860716

Group type: EXPERIMENTAL
Intervention: Sesame oil (SO)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Canola oil (CO)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Sesame-canola oil (SCO)
Number of subjects: 92
Study: 35843915

Group type: EXPERIMENTAL
Intervention: Lidocaine (1 mg/kg and continuous infusion at 2 mg/kg/h)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (continuous infusion at 1.5 gr/kg)
Number of subjects: 120
Study: 33440207

Group type: EXPERIMENTAL
Intervention: Pharmacological thromboprophylaxis (89% of patients)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Heart rate, room-air oxygen saturation (spO2), D-dimer, and C-reactive protein (CRP) levels at admission
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Risk score constructed from heart rate, spO2, D-dimer, and CRP levels
Number of subjects: 73
Study: 36113378

Group type: EXPERIMENTAL
Intervention: JR-142 at 0.25 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: JR-142 at 0.5 mg/kg
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: JR-142 at 1.0 mg/kg
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: JR-142 (all dosages)
Number of subjects: 31
Study: 33713840

Group type: EXPERIMENTAL
Intervention: Collaborative care adapted for co-occurring disorders (CC-COD)
Number of subjects: 900

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 900
Study: 33621809

Group type: EXPERIMENTAL
Intervention: Exenatide (5 mcg, subcutaneously)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 32819740

Group type: EXPERIMENTAL
Intervention: 20-minute session with a certified therapy dog and handler
Number of subjects: 221

Group type: COMPARATOR
Intervention: 20-minute session with a handler only (control group)
Number of subjects: 221
Study: 35756401

Group type: EXPERIMENTAL
Intervention: Integrated psychobehavioral care
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional psychobehavioral care
Number of subjects: 100
Study: 33405475

Group type: EXPERIMENTAL
Intervention: Hospital-based motivational interviewing followed by a 6-month community-based intervention and multiagency support
Number of subjects: 0
Study: 32591475

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natalizumab 600 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34634454

Group type: EXPERIMENTAL
Intervention: ACTIVA Bone Health Program for six months
Number of subjects: 100

Group type: COMPARATOR
Intervention: inactive
Number of subjects: 100
Study: 33586543

Group type: EXPERIMENTAL
Intervention: VIPP‐PRE
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 73
Study: 32624460

Group type: EXPERIMENTAL
Intervention: Post-PCI TIMI 3 flow
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Post-PCI TMPG grade 3
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Post-PCI TMPG
Number of subjects: 96
Study: 34953443

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AA+P)
Number of subjects: 1199

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone (AA+P) in lung metastases patients
Number of subjects: 1199

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1199
Study: 35669371

Group type: EXPERIMENTAL
Intervention: AR‐based rehabilitation methods
Number of subjects: 40

Group type: COMPARATOR
Intervention: Traditional rehabilitation methods
Number of subjects: 40
Study: 34138478

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (200 mg/d) for 7 days or until hospital discharge
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32967151

Group type: EXPERIMENTAL
Intervention: Tetraselmis chuii microalgae supplementation (200 mg per day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (lactose powder 200 mg per day)
Number of subjects: 32
Study: 35324908

Group type: EXPERIMENTAL
Intervention: BASIL+ intervention (Behavioural Activation), delivered remotely, up to eight sessions with a self-help booklet.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BASIL+ intervention (Behavioural Activation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care with additional signposting to self-help resources.
Number of subjects: 0
Study: 32946459

Group type: EXPERIMENTAL
Intervention: 32-item Motor Function Measure (MFM32)
Number of subjects: 110
Study: 32618048

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 58

Group type: COMPARATOR
Intervention: Levocetirizine 5 mg
Number of subjects: 58
Study: 36279463

Group type: EXPERIMENTAL
Intervention: Proposed treatment in randomized experiments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Historical baseline measurements prior to the experiment
Number of subjects: 0
Study: 36368915

Group type: COMPARATOR
Intervention: Group P (0 mg.kg-1 S-ketamine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group S0.3 (0.3 mg.kg-1 S-ketamine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group S0.5 (0.5 mg.kg-1 S-ketamine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group S0.7 (0.7 mg.kg-1 S-ketamine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group S0.3
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group S0.5
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group S0.7
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group S0.5 and Group S0.7
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 32255706

Group type: EXPERIMENTAL
Intervention: Flicker light stimulation in NTG patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flicker light stimulation in healthy individuals
Number of subjects: 12
Study: 34975349

Group type: EXPERIMENTAL
Intervention: Lower limb rehabilitation protocol (LLRP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG) - Instruction of daily care (IDC) only
Number of subjects: 50
Study: 32064970

Group type: EXPERIMENTAL
Intervention: 0.5 g/day omega-3 fatty acids from a plant-based fatty acid supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined ingestion of omega-3 fatty acids and encapsulated fruit, vegetable and berry (FVB) juice powder concentrate
Number of subjects: 0
Study: 616536630

Group type: EXPERIMENTAL
Intervention: Gender-specific school-based program
Number of subjects: 652

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 652
Study: 34347895

Group type: EXPERIMENTAL
Intervention: articaine (4% / 2 mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: tramadol (100 mg/2 mL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: dexamethasone (8 mg/2 mL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: control group (normal saline)
Number of subjects: 120
Study: 33904045

Group type: EXPERIMENTAL
Intervention: Financial incentives on GP level
Number of subjects: 3838

Group type: COMPARATOR
Intervention: Control group (no financial incentives)
Number of subjects: 3838
Study: 34743963

Group type: EXPERIMENTAL
Intervention: 5% nanoHAP dental lotion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo dental lotion
Number of subjects: 30
Study: 36117136

Group type: EXPERIMENTAL
Intervention: Intraoral scan with markers
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intraoral scan without markers
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional impression technique
Number of subjects: 8
Study: 33323529

Group type: EXPERIMENTAL
Intervention: Poseltinib 5 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Poseltinib 10 mg
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Poseltinib 30 mg
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 35719221

Group type: EXPERIMENTAL
Intervention: LSMT (unilateral lumbar PA mobilization at L‐4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SS (static stretching)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of LSMT and SS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (LSMT and SS)
Number of subjects: 30
Study: 33855653

Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg TID plus choline alphoscerate 600 mg BID
Number of subjects: 62

Group type: COMPARATOR
Intervention: Nimodipine 30 mg TID plus placebo BID
Number of subjects: 62
Study: 35951060

Group type: EXPERIMENTAL
Intervention: Aerosol inhalation combined with a vibration expectoration machine
Number of subjects: 110
Study: 33829344

Group type: EXPERIMENTAL
Intervention: Lutetium-Octreotate (LO) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Octreotide long-acting release (O-LAR)
Number of subjects: 0
Study: 35036626

Group type: EXPERIMENTAL
Intervention: Digitalized brief cognitive task intervention (remotely delivered, guided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active (attention placebo) control
Number of subjects: 0
Study: 34506918

Group type: EXPERIMENTAL
Intervention: Yoga module for anger management
Number of subjects: 50